PhoenixBio Co., Ltd. (6190) AI Stock Analysis

• Market Cap: ¥1.73B
• Dividend Yield: N/A
• Average Volume (3M): 360.67K
• Price to Earnings (P/E): 6.1
• Beta (1Y): 0.54
• Revenue Growth: -6.92%
• EPS Growth: -144.96%
• Country: JP
• Employees: 70
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 19.91
• Shares Outstanding: 4,076,933
• 10 Day Avg. Volume: 91,460
• 30 Day Avg. Volume: 360,670
• PEG Ratio: <0.01
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 0.97
• P/FCF Ratio: -15.84
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: ¥437.00 ▼(-9.71% Downside)
• Action: Reiterated Date: 12/10/25
• Date: Action: Reiterated 12/10/25

PhoenixBio Co., Ltd. shows strong technical momentum, which is the most significant positive factor. However, financial performance and valuation are concerning due to negative profitability and cash flow issues, as well as a negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Proprietary PXB-mouse platform

PhoenixBio's proprietary PXB-mouse platform is a durable competitive asset: it creates high technical specialization, recurring demand from drug developers for liver-specific preclinical studies, and barriers to replication. This supports long-term service revenue and differentiates its CRO offerings.

Negative Factors

Negative operating cash flow

Persistently negative operating cash flow erodes internal funding for R&D, facility upkeep, and working capital, forcing reliance on external financing. Over months this can constrain growth initiatives, slow commercialization of services, and increase vulnerability to financing cost shocks.

PhoenixBio Co., Ltd. Business Overview & Revenue Model

Company Description

PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fr...

Read more

PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fr...

How the Company Makes Money

PhoenixBio makes money primarily by monetizing its proprietary humanized animal model platform and related research offerings. Key revenue streams include: (1) Sales and licensing/usage fees for its humanized mouse models and associated biological...

Read more

PhoenixBio makes money primarily by monetizing its proprietary humanized animal model platform and related research offerings. Key revenue streams include: (1) Sales and licensing/usage fees for its humanized mouse models and associated biological...

PhoenixBio Co., Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.49B	1.54B	1.72B	2.12B	1.32B	1.01B
Gross Profit	1.09B	1.11B	1.20B	1.56B	727.79M	588.14M
EBITDA	-245.63M	-396.12M	87.94M	537.42M	-305.81M	-167.27M
Net Income	-448.70M	-445.65M	26.38M	493.33M	-387.97M	-238.00M
Balance Sheet
Total Assets	2.23B	2.31B	2.74B	3.02B	2.28B	2.52B
Cash, Cash Equivalents and Short-Term Investments	1.04B	1.15B	1.39B	1.56B	1.33B	1.33B
Total Debt	503.59M	565.36M	723.93M	1.13B	1.04B	1.04B
Total Liabilities	860.05M	944.82M	946.58M	1.50B	1.45B	1.42B
Stockholders Equity	1.37B	1.37B	1.80B	1.51B	828.15M	1.09B
Cash Flow
Free Cash Flow	0.00	-94.24M	-118.08M	265.12M	9.63M	-284.23M
Operating Cash Flow	0.00	-73.00M	-79.31M	277.49M	16.40M	-101.91M
Investing Cash Flow	0.00	-27.98M	115.36M	-156.34M	-6.97M	-184.78M
Financing Cash Flow	0.00	-128.00M	-244.88M	86.63M	-34.66M	-160.19M

PhoenixBio Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 484.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6190, the sentiment is Negative. The current price of 484 is above the 20-day moving average (MA) of 463.75, above the 50-day MA of 471.82, and above the 200-day MA of 453.69, indicating a bearish trend. The MACD of -7.25 indicates Positive momentum. The RSI at 37.98 is Neutral, neither overbought nor oversold. The STOCH value of 14.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6190.

PhoenixBio Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2342	56 Neutral	¥4.35B	-828.32	―	―	-0.77%	-288.43%
4978	56 Neutral	¥15.50B	120.78	―	―	1.24%	-33.41%
6190	56 Neutral	¥1.73B	6.09	―	―	-6.92%	-144.96%
7774	54 Neutral	¥24.89B	-34.16	―	―	-5.65%	-469.19%
4974	52 Neutral	¥138.12B	-8.84	―	2.18%	-0.16%	-802.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7776	49 Neutral	¥11.35B	-8.14	―	―	-42.49%	-2.37%